[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,75,97,117,142,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":42,"locationsCount":45},"100650860","acute-cardiac-effects-of-ultra-trail-running-100650860",false,"NCT07753694","Acute Cardiac Effects of Ultra-Trail Running","Echocardiographic Assessment of the Acute Impact of an Ultra-Trail Race on Cardiac Function","ULTRA-ECHO","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Registered participants in the \"Trail des Échos\" ultra-trail race (80 km or 160 km)\n* Valid health clearance according to French Athletics Federation requirements\n* Affiliation with a national health insurance system\n* Able to understand study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Known or suspected cardiovascular disease at screening, including coronary artery disease, heart failure, clinically significant arrhythmias, moderate-to-severe valvular disease, uncontrolled hypertension, or prior stroke\n* Acute infection or unstable chronic medical condition (e.g., uncontrolled diabetes, renal, hepatic, respiratory, thyroid, or inflammatory disease)\n* Current treatments that may interfere with cardiovascular or biological assessments (including renin-angiotensin-aldosterone system blockers, chronic diuretics, anticoagulants, or systemic corticosteroids)\n* Use of systemic non-steroidal anti-inflammatory drugs within 3 days before the race or planned during the event\n* Participation in another ultra-endurance race (≥80 km) within 7 days before or after the study race\n* Pregnancy or breastfeeding\n* Inability to provide informed consent or legal protection status\n* Participation in another interventional clinical study",true,"ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to investigate the acute cardiovascular effects of ultra-endurance running using comprehensive echocardiographic assessment combined with biological analyses. The main hypothesis is that participation in an ultra-trail race induces acute and transient changes in cardiac function involving both the left and right ventricles, associated with elevations in cardiac biomarkers, with physiological responses varying according to race distance and training level and showing spontaneous recovery within the days following the event.\n\nAdult amateur runners participating in ultra-trail races of 80 km or 160 km will undergo standardized clinical evaluation, electrocardiography, and transthoracic echocardiography with myocardial deformation analysis at multiple time points, including baseline, pre-effort, during the race, immediately after exercise, and during early recovery approximately one week after the event. Biological sampling will be performed before the race, immediately after exercise, and at follow-up.\n\nThe primary objective is to evaluate acute changes in left ventricular systolic function assessed by global longitudinal strain. Secondary objectives include the assessment of biventricular and atrial function, cardiac and non-cardiac biomarkers, recovery patterns after ultra-endurance exercise, and the influence of race distance, training level, performance level, and sex on cardiovascular responses.\n\nThis exploratory single-center study conducted in France seeks to provide an integrative characterization of cardiac adaptations to extreme endurance exercise and to generate physiological insights that may guide future research and cardiovascular monitoring strategies in endurance athletes.",[26,27,28],"Exercise","Cardiac Function","Echocardiography",[30,31,32,33],"Ultra-endurance exercise","Ultra-trail running","Myocardial strain","Cardiac biomarkers","NOT_YET_RECRUITING","2026-08-04",{"date":37,"type":38},"2026-08-07","ACTUAL",{"date":40,"type":22},"2027-05",{"date":40,"type":22},{"name":43,"class":44},"Central Hospital, Nancy, France","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100623171","levothyroxine-treatment-on-cardiac-function-in-children-with-subclinical-hypothyroidism-100623171","NCT07393165","Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* Patients with stable elevated thyroid-stimulating hormone (TSH) ≥ 4.5 mIU\u002FL with normal free T4 and ft3 in different measurement 4 - 6 weeks apart.\n\nExclusion Criteria:\n\n* Overweight and obesity\n* Hypertension\n* Previous use of levothyroxine, antiepileptic drugs, or cardiac drugs within the last 6 months.\n* Arrhythmia.\n* Congenital or acquired heart disease\n* Liver or kidney disease\n* Hyperlipidemia\n* Diabetes\n* Infectious diseases\n* Respiratory diseases\n* Malignancies","4 Years","15 Years",{"count":56,"type":22},40,"INTERVENTIONAL",[59],"NA","This study aims to evaluate the effect of the treatment with levothyroxine on cardiac function in children with subclinical hypothyroidism.",[62,27,63,64],"Levothyroxine","Children","Subclinical Hypothyroidism","RECRUITING","2026-01-31",{"date":68,"type":38},"2026-02-06",{"date":70,"type":38},"2025-05-24",{"date":72,"type":22},"2026-05-01",{"name":74,"class":44},"Tanta University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100569501","value-of-speckle-tracking-echocardiography-inflammatory-bowel-disease-patients-100569501","NCT06695065","Value of Speckle Tracking Echocardiography Inflammatory Bowel Disease Patients","Value of Speckle Tracking Echocardiography in Early Assessment of Cardiac Function in Inflammatory Bowel Disease Patients","Inclusion Criteria:\n\n* Age (18-60) yrs.\n* Both sexes.\n* Patients with IBD either in active form or in remission.\n\nExclusion Criteria:\n\n* Patients with ischemic heart disease. -Patients with other comorbidities affecting heart as uncontrolled hypertension or diabetes. -\n* Pregnant females.\n* Malignancy","60 Years",{"count":84,"type":22},100,"Value of speckle tracking echocardiography in early assessment of cardiac function in inflammatory bowel disease .",[28,87,27],"Inflammatory Bowel Diseases","2025-09-29",{"date":90,"type":38},"2025-10-02",{"date":92,"type":22},"2025-10-01",{"date":94,"type":22},"2027-12-01",{"name":96,"class":44},"Assiut University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100574633","effect-the-glycemic-control-on-cardiac-function-100574633","NCT06761820","Effect the Glycemic Control on Cardiac Function","Evaluation the Effect of Glycemic Control on Cardiac Function in Patients with Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* type 2 diabetic patients with heart diseases\n\nExclusion Criteria:\n\n* patients with type 1 diabetes mellitus\n* gestational DM\n* CKD patients requiring haemodialysis\n* Immune system disorder",{"count":105,"type":22},200,"Evaluation of the effect of the Glycemic control on cardiac function in patients with type 2 diabetes mellitus",[27,108],"Glycemic Control","2025-01-06",{"date":111,"type":38},"2025-01-07",{"date":113,"type":22},"2025-04",{"date":115,"type":22},"2026-12",{"name":96,"class":44},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":17,"sex":124,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":5},"100492909","automated-fetal-cardiac-function-in-babies-affected-by-heart-diseases-100492909","NCT05698277","Automated Fetal Cardiac Function in Babies Affected by Heart Diseases","Automated Fetal Cardiac Function Parameters in Congenital Heart Disease","Inclusion Criteria:\n\n* Inclusion criteria for the CHD Group are as follows: singleton pregnancies; gestational age between 19+6 and 36+6 weeks gestation, determined by the last menstrual period and confirmed by first trimester ultrasound; isolated congenital cardiac anomaly diagnosed.\n* Inclusion criteria for the Control Group are as follows: singleton pregnancies; gestational age between 19+6 and 27+6 weeks gestation, determined by the last menstrual period and confirmed by first trimester ultrasound; no congenital cardiac anomaly diagnosed\n\nExclusion Criteria common to the 2 groups (Cases and Controls):\n\n* Fetuses whose mothers have comorbidities that have been proven to potentially affect cardiac function including:\n\n  * intrahepatic cholestasis\n  * pre-gestational and gestational diabetes\n  * preeclampsia\n  * growth restricted fetuses defined as estimated fetal weight or abdominal circumference \\\u003C3rd percentile for GA\n* Fetuses with other structural extracardiac anomalies at ultrasound examination\n* Fetuses affected by any diagnosed genetic abnormalities","FEMALE",{"count":126,"type":22},495,"The goal of this international multicentre prospective observational cohort study with a nested case-control study is to test some automated fetal heart functional parameters in healthy babies compared to those affected by a congenital heart condition.\n\nThe main questions it aims to answer are:\n\n* If there is a significant difference between the two populations of infants\n* Whether these parameters could significantly improve the predictive value of actual cardiovascular profile score to predict hydrops Participants will be offered two automated cardiac function assessments between 27+6 and 29+6 gestational weeks and between 34+6 and 36+6 weeks of gestation. Functional parameters will be compared between the two study groups and evaluated over time.",[129,27],"Congenital Heart Defect",[131,132],"Congenital Heart Diseases","Fetal Cardiac Function","2024-12-09",{"date":135,"type":38},"2024-12-10",{"date":137,"type":38},"2023-05-01",{"date":139,"type":22},"2028-02-01",{"name":141,"class":44},"Anna Erenbourg",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":17,"sex":148,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":57,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":45},"100559666","investigation-of-cardiac-function-following-low-intensity-ultrasound-intervention-100559666","NCT06567106","Investigation of Cardiac Function Following Low-Intensity Ultrasound Intervention","Inclusion Criteria:\n\n* Healthy individuals without significant diseases or chronic conditions.\n* Aged between 18 and 65 years.\n* Voluntary participation with signed informed consent.\n* No history of cardiovascular disease.\n\nExclusion Criteria:\n\n* Individuals with heart disease or other conditions that may affect cardiac function measurement.\n* Individuals with implanted electronic devices such as pacemakers or defibrillators.\n* Those on medications that significantly alter heart rate, such as beta-blockers, unless under stable control for a specific period.\n* Individuals at risk of severe complications.","MALE","65 Years",{"count":151,"type":22},6,[59],"The goal of this clinical trial is to investigate the influence of ultrasound on cardiac functrion.\n\nThe main question it aims to answer is:\n\nHow will ultrasound affect the cardiac function?\n\nResearchers will： Apply ultrasound to the body and observe cardiac functions.\n\nParticipants will:\n\nReceive ultrasound application and physiological signal monitoring.",[27],[156,157,158],"Ultrasound","Heart","Cardiac function","2024-10-31",{"date":161,"type":38},"2024-11-04",{"date":163,"type":38},"2024-10-10",{"date":165,"type":22},"2027-10-10",{"name":167,"class":44},"ShanghaiTech University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":176,"targetDuration":4,"studyType":57,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":45},"100513186","short-term-fat-overfeeding-on-the-effects-of-liver-metabolism-100513186","NCT05962190","Short-term Fat Overfeeding on the Effects of Liver Metabolism","The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism.","FOS","Inclusion Criteria:\n\n* The participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 or ≤65 years.\n* Body Mass Index ≥19 ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect liver or adipose tissue metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* The participant is unwilling or unable to give informed consent for participation in the study. - Aged ≤18 or ≥65 years\n* Body Mass Index ≤19 or ≥35kg\u002Fm2\n* Blood haemoglobin \\\u003C135mg\u002FdL for men and \\\u003C120mg\u002FdL for women\n* Donated (or lost) ≥250 ml of blood in the previous two months.\n* On a weight loss diet or have decreased their body weight by \\>5% in the previous 3 months.\n* Have increased their body weight by \\>5% in the previous 3 months.\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* Haemorrhagic disorders\n* Anticoagulant treatment\n* History of albumin allergy\n* Pregnant or nursing mothers\n* Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months History of severe claustrophobia\n* Presence of metallic implants, pacemakers, or are unwilling to remove any piercings\n* History of an eating disorder or any other psychological condition that may affect the participant's ability to adhere to study intervention\u002Fexperimental diets.",{"count":177,"type":22},26,[59],"Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.",[181,27,182,183],"Liver Fat","Lipid Disorder","Adiposity","2023-07-18",{"date":186,"type":38},"2023-07-27",{"date":188,"type":38},"2023-02-15",{"date":190,"type":22},"2028-02",{"name":192,"class":44},"University of Oxford"]